The development of generics in the emerging pharmaceutical market.
Column:Industry Trends Time:2017-12-17
The development of generics in the emerging pharmaceutical market.

Primary market (Tier1) :

China, which alone will account for half of all emerging pharmaceutical market growth, is expected to become the world's second-largest pharmaceutical market by 2015 (including compound Chinese medicine).China is the world's fastest-growing pharmaceutical market, with a compound annual growth rate of 16.7 per cent between 2012 and 2017.Despite China's recent changes to the catalog of national essential drugs and related policies, and the Chinese government to the continuous increase of investment in medical areas as well as the increasingly wealthy Chinese demand for high quality drugs increased out-of-pocket expenses, ensure the steady growth of the market.And the Chinese government is currently implementing a four-year plan to prevent and control chronic diseases (from 2012 to 2015), which already accounts for a significant portion of China's health spending.

Secondary market (Tier2) :

Brazil, although Brazil faced with slowing economic growth, price pressure, as well as government cost control measures and other issues, but as the private medical, health, consumer goods, and the improvement of public health, the market in 2012 to 2017 between the compound annual growth rate can reach 12.7%.

India -- India's compound annual growth rate between 2012 and 2017 is expected to be 12.5 percent.India plans to provide basic medical services to poor and offline families, with a coverage rate of 50 percent (about 630 million people) in 2016.Meanwhile, the private medical scale of urban middle class will be further expanded.Both contribute to growth.

Russia --IMS Health predicts that Russia's compound annual growth rate will reach 10.1 percent between 2012 and 2017.This is mainly because of the huge amount of money the Russian government spends on health care.The Russian government announced the health-care spending 5.6% of GDP in 2012 to 7.5% in 2020, including a national health insurance program, the program covers all retail drugs.However, because Russia to control the prices of medicines and its export relies heavily on oil and gas prices, a slow development of economy as a whole, leading to medical market growth slows.

Tier3 market (Tier3) :

These 17 markets have different income levels, growth rates and the complexity of the healthcare industry.In this study, we divided the three market countries into two groups according to the per capita medical expenditure to show the differences between the two groups.

In 2012, countries with per capita medical spending exceeded $85 -- Poland, Argentina, Turkey, Mexico, venezuela, Romania, Saudi Arabia and Colombia.IMS Health forecasts a compound annual growth rate of 9 per cent between 2012 and 2017, with a total market size of $82bn in 2017.

In 2012, the average per capita medical expenditure was less than $85 -- Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria and Ukraine.IMS Health predicts a compound annual growth rate of 11 per cent between 2012 and 2017, with a total market size of $45 billion in 2017.

The development of generics in the emerging pharmaceutical market.

In 2012, sales of generic drugs in the emerging pharmaceuticals market reached $74 billion, driving more than half of sales growth.Despite the recent slowdown in the field's breakthrough growth, generic drugs still outnumber the original drugs by 15% between 2010 and 2012.Generic drugs can maintain a strong momentum in emerging market countries for several reasons:

Affordability is a big challenge for both governments and patients, and generic drugs are the most economical option.

The protection of intellectual property rights in some countries is lax, so that the generic drug enterprises can obtain the development space.

Government policies and behaviors are mostly local producers, while many local producers are mainly generic drugs.